MediciNova, Inc. (MNOV)☆SHARE ON XDOWNLOAD PNGHealthcare$1.53+10.07%CloseBUYRECOVERY · day 100MNOV▲ BUY$1.53+10.07%☆OverviewFinancialsFinEarningsEarnAnalyst & RatingsAnalystNewsHolders & ETFsHoldOptionsKey statsMarket cap$75MAvg volume39.8KBeta0.62P/E (TTM)-7.04Prediction marketsKalshi · Polymarket · … linkedFull prediction markets →Loading markets…Company newszacks.com · 12d agoMediciNova (MNOV) Reports Q2 Loss, Tops Revenue Estimatesglobenewswire.com · 41d agoMediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patientsglobenewswire.com · 56d agoMediciNova CEO Provides Shareholder Updateglobenewswire.com · 78d agoMediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatmentglobenewswire.com · 91d agoMediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)globenewswire.com · 91d agoMediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)Market news & ticker search · RSS for MNOV
